Indaptus Therapeutics, Inc. Operating Lease, Payments
Indaptus Therapeutics, Inc. (INDP) reported Operating Lease, Payments of $78.18 thousand for the 9-month period ending 2025-09-30, per its 10-Q filed 2025-11-12.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:OperatingLeasePayments · last filed 2025-11-12
- Indaptus Therapeutics, Inc. operating lease, payments for the quarter ending 2025-09-30 was $26.06K, a 3.00% increase year-over-year.
- Indaptus Therapeutics, Inc. operating lease, payments for the quarter ending 2025-06-30 was $26.06K, a 3.00% increase year-over-year.
- Indaptus Therapeutics, Inc. operating lease, payments for the quarter ending 2025-03-31 was $26.06K, a 3.00% increase year-over-year.
- Indaptus Therapeutics, Inc. operating lease, payments for the quarter ending 2024-12-31 was $25.81K, a 2.79% increase year-over-year.
- Indaptus Therapeutics, Inc. operating lease, payments for fiscal 2024 was $101.70K, a 2.47% increase from fiscal 2023.
- Indaptus Therapeutics, Inc. operating lease, payments for fiscal 2023 was $99.25K, a 2.89% increase from fiscal 2022.
- Indaptus Therapeutics, Inc. operating lease, payments for fiscal 2022 was $96.47K, a 129.76% increase from fiscal 2021.
- Indaptus Therapeutics, Inc. operating lease, payments for fiscal 2021 was $41.99K, a 52.38% increase from fiscal 2020.
| Period end | Operating Lease, Payments 3 month | Operating Lease, Payments 6 month | Operating Lease, Payments 9 month | Operating Lease, Payments 12 month |
|---|---|---|---|---|
| 2025-09-30 | $26.06K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $52.12K derived: sum of 2 quarters · filed 2025-11-12 | $78.18K 10-Q · filed 2025-11-12 | $103.98K derived: sum of 4 quarters · filed 2025-11-12 |
| 2025-06-30 | $26.06K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $52.12K 10-Q · filed 2025-08-13 | $77.92K derived: sum of 3 quarters · filed 2025-08-13 | $103.22K derived: sum of 4 quarters · filed 2025-11-12 |
| 2025-03-31 | $26.06K 10-Q · filed 2025-05-14 | $51.87K derived: sum of 2 quarters · filed 2025-05-14 | $77.16K derived: sum of 3 quarters · filed 2025-11-12 | $102.46K derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-12-31 | $25.81K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $51.10K derived: sum of 2 quarters · filed 2025-11-12 | $76.41K derived: sum of 3 quarters · filed 2025-11-12 | $101.70K 10-K · filed 2025-03-13 |
| 2024-09-30 | $25.30K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $50.60K derived: sum of 2 quarters · filed 2025-11-12 | $75.90K 10-Q · filed 2025-11-12 | $101.00K derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $25.30K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $50.60K 10-Q · filed 2025-08-13 | $75.71K derived: sum of 3 quarters · filed 2025-08-13 | $100.42K derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | $25.30K 10-Q · filed 2025-05-14 | $50.41K derived: sum of 2 quarters · filed 2025-05-14 | $75.12K derived: sum of 3 quarters · filed 2025-05-14 | $99.84K derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | $25.11K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $49.82K derived: sum of 2 quarters · filed 2025-03-13 | $74.54K derived: sum of 3 quarters · filed 2025-03-13 | $99.25K 10-K · filed 2025-03-13 |
| 2023-09-30 | $24.72K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $49.43K derived: sum of 2 quarters · filed 2024-11-12 | $74.15K 10-Q · filed 2024-11-12 | $98.62K derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $24.72K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | $49.43K 10-Q · filed 2024-08-12 | $73.91K derived: sum of 3 quarters · filed 2024-08-12 | $97.90K derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-03-31 | $24.72K 10-Q · filed 2024-05-08 | $49.19K derived: sum of 2 quarters · filed 2024-05-08 | $73.19K derived: sum of 3 quarters · filed 2024-05-08 | $95.00K derived: sum of 4 quarters · filed 2024-05-08 |
| 2022-12-31 | $24.48K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13 | $48.47K derived: sum of 2 quarters · filed 2024-03-13 | $70.28K derived: sum of 3 quarters · filed 2024-03-13 | $96.47K 10-K · filed 2024-03-13 |
| 2022-09-30 | $24.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | $45.81K derived: sum of 2 quarters · filed 2023-11-06 | $71.99K 10-Q · filed 2023-11-06 | $94.81K derived: sum of 4 quarters · filed 2023-11-06 |
| 2022-06-30 | $21.81K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $47.99K 10-Q · filed 2023-08-14 | $70.82K derived: sum of 3 quarters · filed 2023-08-14 | $77.25K derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | $26.18K 10-Q · filed 2023-05-11 | $49.01K derived: sum of 2 quarters · filed 2023-05-11 | $55.44K derived: sum of 3 quarters · filed 2023-05-11 | $61.80K derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $22.83K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-17 | $29.26K derived: sum of 2 quarters · filed 2023-03-17 | $35.62K derived: sum of 3 quarters · filed 2023-03-17 | $41.99K 10-K · filed 2023-03-17 |
| 2021-09-30 | $6.43K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $12.79K derived: sum of 2 quarters · filed 2022-11-10 | $19.16K 10-Q · filed 2022-11-10 | |
| 2021-06-30 | $6.37K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $12.73K 10-Q · filed 2022-08-08 | ||
| 2021-03-31 | $6.37K 10-Q · filed 2022-05-12 | |||
| 2020-12-31 | $27.55K 10-K · filed 2022-03-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |